Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.00.

A number of equities research analysts recently weighed in on the company. Leerink Partnrs upgraded Senti Biosciences to a “strong-buy” rating in a research note on Friday, November 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th. Chardan Capital increased their price target on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Leerink Partners initiated coverage on shares of Senti Biosciences in a report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th.

Institutional Trading of Senti Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in SNTI. Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the 3rd quarter worth $117,000. Armistice Capital LLC purchased a new stake in Senti Biosciences in the second quarter valued at about $1,883,000. Finally, Geode Capital Management LLC raised its stake in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares during the last quarter. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Stock Up 2.8%

SNTI opened at $1.11 on Friday. The stock’s fifty day moving average is $1.59 and its two-hundred day moving average is $1.70. The company has a market capitalization of $29.18 million, a P/E ratio of -0.33 and a beta of 2.13. Senti Biosciences has a 52 week low of $1.04 and a 52 week high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last posted its earnings results on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Equities analysts anticipate that Senti Biosciences will post -14.54 earnings per share for the current year.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.